Current Edition


Teva recalls one lot of leukemia med after finding particulates in vial

Particulate contamination of injectable drugs isn’t just a hindrance for manufacturers and customers: it can pose serious health risks, too. And when those drugs are …

Continue Reading →

GSK’s ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms

The future of ViiV Healthcare’s HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around £2 billion ($2.65 billion) …

Continue Reading →